Novavax's XFG-Adapted Nuvaxovid Cleared in U.S., EU, Japan for 2026-27 Season
NVAX sits 47% above its 52-week low of $6.2.
Summary
Regulatory approvals for the XFG-adapted Nuvaxovid in the U.S., EU, and Japan secure Novavax's royalty stream for the 2026-2027 vaccination season. Sanofi is expanding its U.S. marketing campaign and launching in Germany, Canada, and other markets, while Takeda's commercialization in Japan made Nuvaxovid the second-most used COVID-19 vaccine there last season. These approvals trigger milestone payments and ongoing royalties under the Sanofi and Takeda agreements, directly supporting the raised full-year revenue guidance of $235M-$275M. The company's asset-light partnership model means these approvals translate into revenue without additional commercial infrastructure costs. Watch for Sanofi's Phase 4 COMPARE study results and any updates on the C. difficile vaccine pre-IND discussions as additional pipeline catalysts.
At the time of this announcement, NVAX was trading at $9.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $6.20 to $11.97. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.